A Phase 3 interventional study of pegloticase in Gout, sponsored by Savient Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-02.
Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 5th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Savient Pharmaceuticals is the lead sponsor of 6 studies on the registry; none are open to participants now.
Savient Pharmaceuticals has 4 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
Biological: pegloticase
Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
Biological: pegloticase
Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
Biological: pegloticase
8 mg intravenous infusion
Uric Acid (mg/dL)
Uric acid measured at 3 month-intervals
Time frame: Week 13, Week 25, Week 53, Week 101
Tophus Response
Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.
Time frame: Up to 2 years
Patient Reported Outcome: SF-36 Physical Component Summary Score
SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best). The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.
Time frame: RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101
Gout Flare Frequency
The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment
Time frame: Up to 2 years
Gout Flare Incidence
Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.
Time frame: Assessed in 3-month intervals up to 2 years
Subjects completing one of the randomized, controlled Phase 3 clinical trials (RCTs) of pegloticase \[C0405 and C0406 (NCT00325195)\] were invited to participate in this open-label extension study.
| Milestone | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Started | 35 | 25 | 23 | 22 | 28 | 16 |
| Completed | 24 | 17 | 11 | 8 | 8 | 2 |
| Not completed | 11 | 8 | 12 | 14 | 20 | 14 |
Uric acid measured at 3 month-intervals
| mg/dL | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| OLE Week 13 | 1.33 ± 3.103 | 1.91 ± 4.082 | 5.06 ± 4.538 | 9.76 ± 1.346 | 9.66 ± 2.529 | 8.08 ± 3.561 |
| OLE Week 25 | 1.4 ± 3.196 | 1.95 ± 3.761 | 4.69 ± 4.454 | 8.89 ± 3.984 | 9.94 ± 2.646 | 8.09 ± 3.536 |
| OLE Week 53 | 0.87 ± 2.327 | 1.55 ± 3.690 | 2.7 ± 4.255 | 9.18 ± 2.946 | 9.59 ± 2.782 | 6.45 ± 3.248 |
| OLE Week 101 | 0.84 ± 2.619 | 1.47 ± 3.317 | 4.29 ± 3.985 | 7.7 ± 4.244 | 9.42 ± 1.961 | 8.5 ± NA |
Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.
| participants | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Complete Response | 19 | 13 | 10 | 4 | 7 | 3 |
| Partial Response | 4 | 0 | 3 | 4 | 2 | 1 |
SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best). The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.
| units on a scale | q2 RCT, Responder | q4 RCT Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT, Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Baseline value (pre-pegloticase) | 34.92 ± 10.988 | 34.11 ± 10.022 | 27.55 ± 11.405 | 33.71 ± 11.581 | 32.8 ± 10.129 | 36.2 ± 11.926 |
| Final Visit value (LOCF) | 40.40 ± 13.393 | 40.82 ± 7.482 | 30.34 ± 11.132 | 37.68 ± 10.298 | 34.76 ± 11.413 | 38.8 ± 13.155 |
The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment
| Flares | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Months 1-3 | 0.4 ± 0.69 | 0.8 ± 0.90 | 2.3 ± 2.91 | 0.6 ± 0.90 | 1.3 ± 1.49 | 1.5 ± 1.41 |
| Months 4-6 | 0.4 ± 0.96 | 0.7 ± 0.95 | 1.3 ± 2.17 | 1.0 ± 1.73 | 0.8 ± 0.94 | 0.8 ± 1.18 |
| Months 7-9 | 0.0 ± 0.17 | 0.3 ± 0.54 | 1.2 ± 1.80 | 0.6 ± 1.20 | 0.6 ± 0.97 | 0.4 ± 1.01 |
| Months 10-12 | 0.1 ± 0.30 | 0.2 ± 0.51 | 0.6 ± 1.18 | 0.9 ± 1.34 | 0.9 ± 1.46 | 0.4 ± 0.63 |
| Months 16-18 | 0.1 ± 0.25 | .3 ± 0.44 | 0.2 ± 0.40 | 0.7 ± 1.18 | 0.6 ± 0.85 | 0.4 ± 0.89 |
| Months 22-24 | 0.1 ± 0.37 | 0.1 ± 0.23 | 0.4 ± 0.67 | 0.3 ± 0.65 | 0.6 ± 0.53 | 0.7 ± 1.15 |
Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.
| Percentage of participants | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Months 1-3 | 25.7 | 56.0 | 65.2 | 45.5 | 67.9 | 68.8 |
| Months 4-6 | 23.5 | 40.0 | 45.0 | 35.0 | 50.0 | 38.5 |
| Months 7-9 | 3.0 | 24.0 | 43.8 | 27.8 | 42.9 | 22.2 |
| Months 10-12 | 9.4 | 16.7 | 28.6 | 47.1 | 45.0 | 28.6 |
| Months 16-18 | 6.5 | 25.0 | 18.2 | 33.3 | 38.9 | 20.0 |
| Months 22-24 | 3.4 | 5.3 | 27.3 | 25.0 | 55.6 | 33.3 |
Collected over Up to 30 days post-treatment (maximum of 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| q2 RCT, Responder | — | 9/35 (25.7%) | 34/35 (97.1%) |
| q4 RCT, Responder | — | 7/25 (28%) | 25/25 (100%) |
| Placebo in RCT, q2 in OLE | — | 8/23 (34.8%) | 23/23 (100%) |
| q2 RCT, Non-responder | — | 7/22 (31.8%) | 21/22 (95.5%) |
| q4 RCT Non-responder | — | 12/28 (42.9%) | 28/28 (100%) |
| Placebo in RCT, q4 in OLE | — | 8/16 (50%) | 15/16 (93.8%) |
| Event | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| Infusion related reactionGeneral disorders | 1/35 | 0/25 | 4/23 | 1/22 | 3/28 | 3/16 |
| DiarrhoeaGastrointestinal disorders | 0/35 | 1/25 | 2/23 | 0/22 | 0/28 | 0/16 |
| Deep Vein ThrombosisVascular disorders | 0/35 | 0/25 | 2/23 | 0/22 | 1/28 | 0/16 |
| Chest painGeneral disorders | 0/35 | 1/25 | 0/23 | 0/22 | 2/28 | 0/16 |
| AppendicitisInfections and infestations | 0/35 | 0/25 | 0/23 | 0/22 | 0/28 | 1/16 |
| FasciitisMusculoskeletal and connective tissue disorders | 0/35 | 0/25 | 0/23 | 0/22 | 0/28 | 1/16 |
| MyositisMusculoskeletal and connective tissue disorders | 0/35 | 0/25 | 0/23 | 0/22 | 0/28 | 1/16 |
| Renal Failure AcuteRenal and urinary disorders | 1/35 | 0/25 | 0/23 | 1/22 | 1/28 | 1/16 |
| Lumbar RadiculopathyNervous system disorders | 0/35 | 0/25 | 0/23 | 0/22 | 0/28 | 1/16 |
| GlaucomaEye disorders | 0/35 | 0/25 | 0/23 | 0/22 | 0/28 | 1/16 |
| Event | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE |
|---|---|---|---|---|---|---|
| GoutMusculoskeletal and connective tissue disorders | 15/35 | 19/25 | 19/23 | 16/22 | 24/28 | 13/16 |
| Infusion Related ReactionGeneral disorders | 7/35 | 6/25 | 13/23 | 8/22 | 19/28 | 12/16 |
| Back PainMusculoskeletal and connective tissue disorders | 5/35 | 4/25 | 9/23 | 3/22 | 3/28 | 1/16 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 5/35 | 8/25 | 4/23 | 1/22 | 6/28 | 2/16 |
| Upper Respiratory Tract InvectionInfections and infestations | 8/35 | 8/25 | 4/23 | 3/22 | 4/28 | 0/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/35 | 7/25 | 6/23 | 1/22 | 8/28 | 0/16 |
| Oedema PeripheralGeneral disorders | 7/35 | 6/25 | 5/23 | 1/22 | 2/28 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 7/35 | 6/25 | 3/23 | 2/22 | 4/28 | 0/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/35 | 2/25 | 3/23 | 0/22 | 0/28 | 1/16 |
| SinusititsInfections and infestations | 4/35 | 2/25 | 1/23 | 5/22 | 3/28 | 0/16 |
| Age, Categorical(Participants) | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 17 | 18 | 16 | 23 | 11 | 105 |
| >=65 years | 15 | 8 | 5 | 6 | 5 | 5 | 44 |
| Age Continuous(years) | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE | Total |
|---|---|---|---|---|---|---|---|
| Mean | 62.4 ± 13.66 | 58.6 ± 13.59 | 56.6 ± 10.53 | 52.0 ± 13.12 | 53.5 ± 12.25 | 54.6 ± 13.62 | 56.8 ± 13.19 |
| Sex: Female, Male(Participants) | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE | Total |
|---|---|---|---|---|---|---|---|
| Female | 10 | 7 | 4 | 4 | 4 | 3 | 32 |
| Male | 25 | 18 | 19 | 18 | 24 | 13 | 117 |
| Region of Enrollment(participants) | q2 RCT, Responder | q4 RCT, Responder | Placebo in RCT, q2 in OLE | q2 RCT, Non-responder | q4 RCT Non-responder | Placebo in RCT, q4 in OLE | Total |
|---|---|---|---|---|---|---|---|
| United States | 32 | 22 | 22 | 17 | 27 | 13 | 133 |
| Canada | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Mexico | 3 | 2 | 0 | 5 | 1 | 3 | 14 |
The record gives a start of Dec 2006, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegloticase
Savient Pharmaceuticals